hematology/oncology

DCI member and physician-scientist Sandeep Dave, MD, MS, has been named the Wellcome Clinical Distinguished Professor of Medicine.

Jacob Keller, MHA, has joined DCI as administrative director for Hematologic Malignancies & Cellular Therapies, effective January 1.

Join faculty speakers from the DCI Hematologic Malignancies & Cellular Therapy Disease Group on Oct. 5 for a virtual OncLive summit on leukemia & lymphoma.

The new Duke Blood Cancer Center opens up the opportunity to transition some cancer treatments from the inpatient to the outpatient setting and the infusion room is open every day.

Ken Young, MD, PhD, will assume the role of chief, Hematopathology Division and DCI Blood Cancer Pathology Service, on Jan. 1, 2021.

The Duke Cancer Institute Virtual Grand Rounds Series, came to a successful summer close with its final session on June 19.

Lifetime Achievement Award Winner Keith Sullivan, MD, and colleagues reflect on his career and passion.

Medical oncologist Edwin P. Alyea, III, MD, formerly with Dana-Farber Cancer Institute, has been named chief medical officer (CMO) for Duke Cancer Institute.

ICYMI the AACI's Physician Clinical Leadership Initiative (PCLI) presented a two-part webinar series on hereditary cancer programs and cancer risk assessment.

Duke Cancer Institute hematologic oncologist Joseph Moore, MD, after 44 years, retired from clinical practice this summer. He and colleagues reflect on his legacy.

DCI blood cancer researchers shared new scientific discoveries and treatments in lymphomas, leukemias, and multiple myeloma at OncLive summit.

After college graduation, Shannon Voelkel started her “dream job” working for a well-known interior design firm. A year-and-a-half later, she learned life had other plans.